It Seems Neurocrine Biosciences Incorporated (NASDAQ:NBIX) Will Go Down. Just Reported More Shorted Shares

August 30, 2017 - By Marguerite Chambers

 It Seems Neurocrine Biosciences Incorporated (NASDAQ:NBIX) Will Go Down. Just Reported More Shorted Shares

Investors sentiment decreased to 1.06 in Q4 2016. Its down 0.03, from 1.09 in 2016Q3. It is negative, as 33 investors sold Neurocrine Biosciences, Inc. shares while 67 reduced holdings. 23 funds opened positions while 83 raised stakes. 82.52 million shares or 1.88% less from 84.11 million shares in 2016Q3 were reported.
Nomura Inc holds 9,031 shares or 0% of its portfolio. Westfield Cap Lp stated it has 1.39M shares or 0.47% of all its holdings. Tekla Capital Lc, a Massachusetts-based fund reported 391,869 shares. Neuberger Berman Grp Inc Limited Liability Com has 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Natl Bank Of America Corp De owns 242,132 shares. Woodstock Corporation reported 0.13% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Blackrock Inc, New York-based fund reported 35,149 shares. Point72 Asia (Hong Kong) accumulated 7,267 shares. Sg Americas Securities Ltd Co stated it has 59,669 shares. Deutsche Bank Ag accumulated 0.03% or 848,185 shares. 12.95 million were accumulated by Fmr Ltd Limited Liability Company. Fifth Third Bancorporation has 499 shares for 0% of their portfolio. Rothschild Asset Management Inc invested in 42,148 shares. Amalgamated National Bank & Trust accumulated 15,315 shares or 0.03% of the stock. Dafna Capital Mngmt Ltd Liability Corporation has invested 2.24% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Since May 1, 2017, it had 0 insider purchases, and 8 insider sales for $10.02 million activity. $532,700 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by Lippoldt Darin. Another trade for 10,000 shares valued at $550,000 was sold by Grigoriadis Dimitri E.. Nevinny Corinne H had sold 5,000 shares worth $269,900 on Friday, May 5. Shares for $1.16 million were sold by GORMAN KEVIN CHARLES. On Thursday, May 18 OBrien Christopher Flint sold $5.63 million worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 105,634 shares. On Monday, May 1 Gano Kyle sold $810,000 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) or 15,000 shares.

The stock of Neurocrine Biosciences Incorporated (NASDAQ:NBIX) registered an increase of 15.97% in short interest. NBIX’s total short interest was 8.12M shares in August as published by FINRA. Its up 15.97% from 7.00M shares, reported previously. With 1.13 million shares average volume, it will take short sellers 7 days to cover their NBIX’s short positions. The short interest to Neurocrine Biosciences Incorporated’s float is 9.47%.

About 262,268 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since August 30, 2016 and is uptrending. It has underperformed by 4.19% the S&P500.

Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development platform, focused on neurological and endocrine based diseases and disorders. The company has market cap of $4.68 billion. The Company’s three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. It currently has negative earnings. The Company’s product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 10 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 19 analyst reports since August 18, 2015 according to SRatingsIntel. Piper Jaffray maintained the stock with “Overweight” rating in Thursday, October 8 report. Needham initiated the shares of NBIX in report on Tuesday, October 18 with “Buy” rating. The firm earned “Buy” rating on Thursday, November 3 by Deutsche Bank. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Oppenheimer on Friday, August 4. BMO Capital Markets maintained it with “Buy” rating and $7500 target in Friday, July 21 report. The firm earned “Buy” rating on Tuesday, July 11 by H.C. Wainwright. The stock has “Buy” rating by Oppenheimer on Wednesday, July 5. The company was reinitiated on Tuesday, August 18 by Jefferies. Oppenheimer upgraded Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Friday, January 27 to “Outperform” rating. On Friday, August 4 the stock rating was maintained by Cowen & Co with “Buy”.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: Seekingalpha.com which released: “Neurocrine Stumbles With Ingrezza In Pediatric Tourette’s” on May 24, 2017, also Seekingalpha.com with their article: “Neurocrine Biosciences: Ingrezza’s Strong Launch, Pipeline To Create Value” published on August 16, 2017, Seekingalpha.com published: “Neurocrine Biosciences Off To A Good Start With Ingrezza” on August 04, 2017. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: Prnewswire.com and their article: “Neurocrine Biosciences, Inc. Prices $450.0 Million Convertible Senior Notes …” published on April 26, 2017 as well as Nasdaq.com‘s news article titled: “TimesSquare Capital Management, LLC Buys Imax Corp, Neurocrine Biosciences Inc …” with publication date: August 10, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.